DUBLIN, Ireland, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL) today announced its financial results for the second quarter of 2017.
Highlights Include:
Total revenues for the second quarter 2017 were $46.3 million, compared to $38.9 million in the second quarter 2016.
